[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485794":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":26,"id":67,"slug":26,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Monastir","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"atherolive","ACTIVE_COMPARATOR","In this Arm the patient will receive the study drug (atherol) that will be prescribed at a dose of 400 mg, once a day for 3 months.",[13],"Drug: Atherolive",{"label":15,"type":16,"description":17,"interventionNames":18},"placebo atherolive","PLACEBO_COMPARATOR","In this Arm patients will receive the placebo at a dose of 400 mg once a day for 3 months.",[19],"Drug: Placebo Atherolive",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Atherolive","The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Atherolive","The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.",[15],[32],{"name":33,"affiliation":5,"role":34},"Nouira Semir, Pr","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Nouira semir, Pr","CONTACT","73106046","216","semir.nouira@rns.tn",{"name":43,"role":38,"phone":39,"phoneExt":40,"email":44},"Bel Hadj Ali khaoula, MD","belhadjalikhaoula@yahoo.fr",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Semir Nouira","RECRUITING","Monastir","Monastir Tunisia","5000","Tunisia","TN",{"type":55,"coordinates":56},"Point",[57,58],10.82617,35.77799,{"lat":58,"lon":57},[61],{"name":47,"role":38,"phone":62,"phoneExt":26,"email":63},"73106000","semir.nouira.urg@gmail.com",{"type":34,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Pr. Semir Nouira","clinical proffesor","100485794",false,"NCT05605704","Olive Leaf Extracts in the Control of Diabet","Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Diabet","Dia-Athr","Inclusion Criteria:\n\n* Patients over 18 years of age with:\n* diabetes.\n\nExclusion Criteria:\n\n* Exclusion criteria: None.","ALL","18 Years","100 Years",{"count":78,"type":79},500,"ESTIMATED","INTERVENTIONAL",[82,83],"PHASE2","PHASE3","This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).\n\nPatients over 18 years of age with:\n\n-Diabets",[86],"Diabetes Mellitus, Type 2",[88,23],"diabetes","2025-06-01",{"date":91,"type":92},"2025-06-03","ACTUAL",{"date":94,"type":92},"2023-01-01",{"date":96,"type":79},"2025-12-15",{"name":5,"class":6},1]